CVS Health (CVS)
(Delayed Data from NYSE)
$57.11 USD
-0.74 (-1.28%)
Updated Aug 9, 2024 04:00 PM ET
4-Sell of 5 4
A Value D Growth D Momentum B VGM
CVS Health (CVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$69.83 | $94.00 | $59.00 | 22.27% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for CVS Health comes to $69.83. The forecasts range from a low of $59.00 to a high of $94.00. The average price target represents an increase of 22.27% from the last closing price of $57.11.
Analyst Price Targets (23)
Broker Rating
CVS Health currently has an average brokerage recommendation (ABR) of 1.98 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 1.98 a month ago based on 25 recommendations.
Of the 25 recommendations deriving the current ABR, 11 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 44% and 12% of all recommendations. A month ago, Strong Buy made up 44%, while Buy represented 12%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 11 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 11 | 11 | 11 | 11 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.98 | 1.98 | 1.98 | 1.98 | 1.94 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Cantor Fitzgerald & Co | Sarah James | Hold | Hold |
8/8/2024 | Evercore Partners | Elizabeth Anderson | Strong Buy | Strong Buy |
8/7/2024 | SVB Securities | Michael Cherny | Hold | Hold |
8/6/2024 | Not Identified | Not Identified | Hold | Hold |
7/10/2024 | Edward D. Jones & Company | John Boylan | Hold | Hold |
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Hold |
5/8/2024 | Argus Research Corp. | Christopher Graja | Not Available | Strong Buy |
5/7/2024 | Cowen & Co. | Charles Rhyee | Strong Buy | Hold |
5/2/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
5/2/2024 | UBS | Kevin Caliendo | Strong Buy | Hold |
5/2/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
4/8/2024 | Not Identified | Not Identified | Hold | Hold |
4/8/2024 | Wells Fargo Securities | Stephen Baxter | Hold | Hold |
3/15/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
2/9/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
12/22/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.98 |
ABR (Last week) | 1.98 |
# of Recs in ABR | 25 |
Average Target Price | $69.83 |
LT Growth Rate | 10.90% |
Industry | Retail - Pharmacies and Drug Stores |
Industry Rank by ABR | 249 of 253 |
Current Quarter EPS Est: | 1.79 |